The genetic mutation behind Huntington’s disease may cause neurodegeneration through the production a toxic form of the huntingtin protein,…
Articles by Marisa Wexler, MS
The once-daily oral therapy Ingrezza (valbenazine) — already marketed in the U.S. as a treatment for a movement disorder…
When young, healthy progenitors of neuron-supporting cells called glia are transplanted into the adult brain, they can grow and replace…
Scientists have figured out the first molecular events in the formation of toxic huntingtin protein clumps in Huntington’s disease.
The oral therapy valbenazine significantly reduces involuntary muscle contractions, or chorea, and patient-reported disease burden in people with…
Austedo XR, an extended-release oral formulation of Austedo (deutetrabenazine), is now commercially available in the U.S. as a treatment…
The Phase 3 PROOF-HD trial failed to meet its main goal of showing that pridopidine, Prilenia Therapeutics’ experimental…
Asklepios Biopharmaceutical (AskBio) has launched a first-in-human clinical trial testing AB-1001 — an experimental gene therapy designed to modulate…
A Phase 1/2a clinical trial testing VO659, Vico Therapeutics’ experimental therapy, in people with Huntington’s disease and other…
Using machine learning, a form of artificial intelligence, researchers were able to cluster people with Huntington’s disease into three…